BMY
—
—
Loading…
—
—
MASTER
—
—
ESEN VERDICT
Analyzing…
Horizon6–12M
Confidence—
Data coverage—
ESEN MASTER EQUITY ANALYSIS: BMY
Summary Scorecard
| Dimension | Grade | Score | Evidence | Horizon |
|---|---|---|---|---|
| FINAL ESEN MASTER SCORE | B+ | 73 | Positive EPS momentum (26.27% YoY), low valuation risk (PEG 0.70), high dividend yield (3.96%), offset by weak revenue growth and low beta | 6-12M |
| SA Quality/Value Composite | B | 71 | Forward PE 8.89 suggests deep valuation discount; dividend safety supported by mature earnings profile; however TTM revenue opaque | 6-12M |
| Zacks Earnings Momentum | A | 82 | EPS growth 26.27% YoY significantly outpaces revenue growth (1.78%); PEG ratio of 0.70 indicates growth priced efficiently below market comps | 6-12M |
| Institutional & Smart Money Flow | C+ | 62 | Average volume 10.48M shares; no explicit insider activity or institutional concentration data visible; beta 0.22 reflects defensive positioning | 3-6M |
| Growth Sustainability & Moat | C | 58 | Hyper-growth flag active; revenue growth 1.78% weak relative to EPS expansion; pharmaceutical sector faces patent cliffs and generic erosion; sector moat questioned | 12M+ |
| Valuation & Safety (Pre-Penalty) | A- | 85 | PE 18.48 vs sector median ~20; forward PE 8.89 exceptionally low; week-52 range $42.52–$64.97 shows 52W return +33.87%; dividend yield 3.96% premium to risk-free | 6-12M |
| Penalty Overlay | WATCH | -8 | Weak balance sheet flagged; revenue growth significantly lags EPS (quality concern); earnings sustainability uncertain given opaque TTM revenue and missing earnings date | 3M+ |
| CONFIDENCE SCORE | C+ | 65 | Data gaps: no TTM revenue, no ex-dividend date, no target price consensus, no earnings date; reliance on backward-looking metrics; limited forward guidance visibility | 3-6M |
| Volatility & Drawdown Risk | A | 88 | Beta 0.22 (very low); price stable near 52W high; $21.45 drawdown cushion to low; defensive pharmaceutical holdings typical of low-vol portfolios | 3-6M |
| Crowding Risk Flag | MODERATE | 62 | High dividend yield and low volatility attract passive income and defensive allocations; sector-wide rotational risk if rates normalize; no concentration metrics disclosed | 3-12M |
Key Metrics Snapshot
Current Price
$63.64
P/E Ratio
18.48
Forward P/E
8.89
PEG Ratio
0.70
EPS (TTM)
$3.36
EPS Growth YoY
+26.27%
Revenue Growth YoY
+1.78%
Dividend Yield
3.96%
Dividend per Share
$2.51
Beta
0.22
Market Cap
$130.4B
52W Return
+33.87%
Peer Context & Sector Positioning
Bristol-Myers Squibb competes within the large-cap pharmaceuticals cohort alongside JNJ, MRK, ABBV, and LLY. BMY's forward PE of 8.89 places it in the deeply discounted tier relative to historical peer medians (~15–18x). The exceptional EPS growth of 26.27% YoY, paired with a PEG of 0.70, suggests market skepticism about earnings sustainability—a hallmark of quality concerns. Revenue growth of only 1.78% YoY is anemic for a firm flagged as "hyper-growth," indicating that EPS expansion is likely driven by margin compression (operational leverage) or accounting adjustments rather than top-line momentum. The sector faces structural headwinds: patent cliff risk, biosimilar erosion, and regulatory pricing pressures. BMY's low beta (0.22) and 3.96% dividend yield position it as a defensive hedge, attracting income-focused and risk-averse capital. Peer comparison suggests BMY is valued for yield and stability rather than growth, making it a "bond proxy" rather than a growth story.
Two-Horizon Insight
1–3 Month Horizon (Tactical): Near-term price action is anchored by low volatility (beta 0.22) and strong recent performance (+33.87% over 52 weeks). The stock trades near its 52-week high ($64.97), suggesting limited upside surprise. Immediate risks include dividend sustainability scrutiny (given weak revenue backdrop) and technical consolidation. A re-test of support near $63–$63.50 would remain constructive for income-focused holders. Crowding risk is moderate among dividend seekers; any rotation out of low-volatility plays could trigger sharp underperformance.
6–12 Month Horizon (Strategic): Medium-term outlook hinges on earnings quality verification. The 26.27% EPS growth must be validated against actual cash generation and revenue stabilization. Forward PE of 8.89 offers a valuation cushion, but only if EPS guidance does not cut materially. The "hyper-growth" flag combined with "weak balance sheet" and "low profitability" raises red flags about leverage and operational stress. Patent cliffs (typical in pharma) and generic competition will pressure margins. Dividend coverage is under watch if EPS revisions occur. Institutional flows may deteriorate if earnings momentum stalls. Target upside is capped at ~$68–$70 absent positive surprise; downside risk extends to $55–$58 if EPS guidance disappoints or dividend sustainability is questioned.
ESEN Master Verdict
BMY is a HOLD-to-BUY-on-DIPS for defensive income seekers with moderate confidence. Forward PE 8.89 and 3.96% yield are attractive, but wide divergence between EPS growth (26%) and revenue growth (1.78%) signals earnings quality concerns. Weak balance sheet and opaque TTM revenue pose materiality risk to dividend sustainability. Best suited for risk-averse, yield-focused portfolios; growth investors should await revenue acceleration or higher conviction on EPS durability. Confidence 65/100 (data gaps constrain conviction). Fair value range $58–$70; accumulate on $60–$62 dips.
ESEN MASTER SCORE: 73 / 100
Institutional Grade: B+ | Risk Profile: LOW | Income Profile: HIGH | Growth Profile: QUESTIONABLE
Institutional Grade: B+ | Risk Profile: LOW | Income Profile: HIGH | Growth Profile: QUESTIONABLE
ESEN Institutional Analysis
BMY Systematic Research
Bristol-Myers Squibb demonstrates a distinctive profitability profile within the pharmaceutical sector, with return on equity reaching 41.64% against a leverage ratio of 2.44. The company trades at a price-to-earnings multiple of 19.72 on trailing twelve-month earnings of $3.36 per share, positioning the valuation at the lower end of peer comparisons relative to Eli Lilly and Merck. The current price of $57.62 sits within 8% of the 52-week high of $62.89, reflecting recent market recognition of fundamental improvements.
Systematic screening highlights several operational strengths in the business model:
- Margin structure: Operating margin of 17.1% and net margin of 12.33% indicate sustained pricing power despite competitive pressures in specialty pharmaceuticals
- Profitability expansion: EPS growth of 26.27% year-over-year significantly outpaces revenue growth of 1.78%, suggesting operational leverage and portfolio optimization
- Defensive characteristics: Beta of 0.23 positions BMY among the lowest-volatility names in large-cap healthcare, appealing to risk-adjusted systematic strategies
Research perspective identifies execution risks worth monitoring. The debt-to-equity ratio of 2.44 reflects acquisition-driven balance sheet expansion, requiring consistent cash generation to service obligations. Revenue growth trailing industry peers at 1.78% signals patent cliff pressures that demand successful late-stage pipeline conversion.
The price-to-book ratio of 5.94 versus book value per share of $9.18 indicates market expectations for sustained returns well above cost of capital. Relative to JNJ and LLY, Bristol-Myers trades at a valuation discount despite superior ROE metrics, a divergence that quantitative models flag for portfolios emphasizing quality factors in defensive sectors.
Analysis updated monthly based on systematic screening of fundamentals, profitability, growth, and peer positioning.